Research Ethics Approval for a Clinical Trial
A DHA-licensed hospital plans to conduct a clinical trial on a new diabetes drug. The principal investigator (PI) submits a protocol to the hospital's research ethics committee (REC) for approval. The trial involves 200 patients, including 20 pregnant women with gestational diabetes. The PI has not obtained a DHA research permit, arguing that REC approval is sufficient. The protocol includes a placebo-controlled arm, meaning some patients will receive a placebo instead of standard care. The REC is concerned about the inclusion of pregnant women and the use of placebo when effective treatment exists. The PI argues that the trial is necessary to test the drug's efficacy and that participants will sign informed consent. The REC must decide whether to approve, require modifications, or reject the study.
1. What DHA regulatory requirements apply to this clinical trial, and what are the REC's obligations?
Read the worked answer
Under DHA regulations for research and clinical trials:
- Research permit: All clinical trials conducted in Dubai must obtain a research permit from DHA's research oversight body, in addition to REC approval. The PI's argument that REC approval is sufficient is incorrect. The REC must ensure the PI has applied for or obtained the DHA permit before final approval.
- Ethical review: The REC must ensure the trial meets ethical standards, including:
- Risk-benefit: The use of placebo when effective treatment exists may be unethical if it exposes participants to harm. The REC must scrutinize the justification.
- Vulnerable populations: Pregnant women are a vulnerable group. Their inclusion requires special justification and safeguards. The REC must ensure that the potential benefits outweigh risks and that informed consent is properly obtained.
- Informed consent: Must be comprehensive, especially for pregnant women and regarding placebo.
- Compliance with national laws: The trial must comply with UAE federal laws on medical research and DHA policies. The REC's obligation is to protect participants and ensure regulatory compliance. It cannot approve the trial without the DHA permit and must address the ethical concerns.
2. What decision should the REC make regarding the placebo arm and the inclusion of pregnant women? Provide reasoning.
Read the worked answer
The REC should not approve the trial as submitted. It should require modifications:
- Placebo arm: If standard effective treatment exists for diabetes, using placebo instead of active treatment may be unethical unless there is a compelling methodological reason and safeguards (e.g., rescue medication, close monitoring). The REC should require the PI to justify the placebo or replace it with an active comparator. Given the availability of effective diabetes treatments, a placebo-controlled design is likely unacceptable.
- Pregnant women: Including pregnant women with gestational diabetes is high-risk. The REC should require:
- Strong preclinical and clinical evidence of safety for the drug in pregnancy.
- A separate protocol section detailing risks and benefits.
- Assurance that standard care is not withheld.
- Informed consent that clearly explains risks to the fetus.
- Consideration of excluding pregnant women until safety is established, or limiting to a substudy with additional oversight.
- DHA permit: The REC should withhold approval until the DHA research permit is obtained. The REC's decision should prioritize participant safety and ethical principles. It may allow the trial to proceed with an active comparator and exclusion of pregnant women, or with stringent safeguards if justified.